Food and Drug Administration Silver Spring, MD 20993

June 7, 2019

Dear Colleague:

On behalf of the U.S. Food and Drug Administration (FDA), the Office of External Affairs, Stakeholder Engagement Staff, thanks you for your participation at the FDA's Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds Public Hearing held on Friday, May 31, 2019. Your participation was essential to enhance our awareness of the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds.

Opening remarks by Norman E. "Ned" Sharpless MD, Acting Commissioner of Food and Drugs, are available at: https://www.fda.gov/news-events/speeches-fda-officials/remarks-dr-sharpless-fda-public-hearing-scientific-data-and-information-about-products-containing.

A recording of the entire hearing is available in four distinct segments. Each segment is in order based on the hearing's agenda. Event materials are available at: https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/scientific-data-and-information-about-products-containing-cannabis-or-cannabis-derived-compounds.

- Segment 1 https://collaboration.fda.gov/pr8clhusaf72/ (opening until morning break)
- Segment 2 https://collaboration.fda.gov/p69wh5mase6j/ (after morning break until lunch)
- Segment 3 https://collaboration.fda.gov/plubcsivwhe6/ (after lunch until afternoon break)
- Segment 4 https://collaboration.fda.gov/pihtiz8flmf7/ (after afternoon break until closing)

We plan to publish the hearing transcript and slide decks in approximately 30 days at https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/scientific-data-and-information-about-products-containing-cannabis-or-cannabis-derived-compounds.

Please remember to submit your comments and supporting data to the docket at <u>FDA-2019-N-1482</u> by 11:59 p.m. (ET), Tuesday, July 2, 2019.

Again, thank you for your interest related to products containing cannabis or cannabis-derived compounds and we look forward to your continued participation on this topic.

Sincerely,

Stakeholder Engagement Staff
Office of External Affairs
U.S. Food and Drug Administration